Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Prokarium Receives £0.4m Grant to Develop Next Generation Vaccines

Published: Tuesday, March 12, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Grant will allow Prokarium to complete preclinical work on Typhetec®.

A consortium comprising vaccine developer Prokarium Ltd and the University of Birmingham’s Institute of Microbiology and Infection has received an award for ‘advancing the industrial application of synthetic biology’.

The £0.4m grant from the Technology Strategy Board (TSB), the UK’s innovation agency, and the Biotechnology and Biological Sciences Research Council (BBSRC) has been earmarked to help fund the development of Prokarium’s Vaxonella® oral vaccine delivery platform as well as two specific vaccine candidates.

Prokarium, a biotechnology start-up company based in Keele, Staffordshire and London, UK, develops cutting-edge genetic technologies to engineer immune-cell-targeting bacteria that express vaccines from within the body, creating the next generation of safe, affordable, oral vaccines.

The grant will allow Prokarium to complete preclinical work on its first pipeline product Typhetec®, a dual oral vaccine against typhoid and ETEC, a major cause of diarrhoea.

In addition, this grant will enable R&D to commence on a novel vaccine against Clostridium difficile, a major cause of colitis in the elderly.

Currently there are no vaccines against ETEC, a bacterium responsible for between 300,000 and 500,000 deaths annually, including children in developing countries.

In addition, every year more than 10 million travellers contract diarrhoea caused by ETEC, which costs €200m annually in medical resources within the EU, and accounts for €450m in lost productivity.

Similarly, there is no vaccine against C. difficile, responsible for approximately 900,000 cases of colitis a year across Europe and North America, with an estimated cost of care burden of over $7 billion.

With this funding from the TSB and BBSRC, Prokarium and the University of Birmingham will be able to test candidates that have the potential to be developed into oral vaccines for both the developed and emerging markets.

Carl-Johan Spak, CEO of Prokarium, said: “We are very pleased that the TSB and BBSRC awarded our consortium this funding, which will not only bring us closer to creating the next generation of oral vaccines against two very important diseases, but also recognizes Prokarium as an innovative synthetic biology company.”

Prof Ian Henderson, University of Birmingham adds: "Prokarium's Vaxonella platform will revolutionize the way we protect people from infectious and non-infectious disease. I am excited by the opportunity to assist Prokarium in the development of an ETEC vaccine based on Vaxonella. Success in this important endeavour will give the gift of life to millions of children who would otherwise suffer or die from this devastating disease".


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Tuesday, August 04, 2015
Prokarium Acquires Key Oral Vaccine Technology from Emergent BioSolutions
Prokarium to combine Typhella™ and spi-VEC™ with its genetic and formulation technologies to form Vaxonella™.
Tuesday, July 10, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!